Drugs Made In America Acquisition II Corp. (DMIIU) Non-Current Deffered Revenue (2025)

Drugs Made In America Acquisition (DMIIU) has reported Non-Current Deffered Revenue for 1 consecutive years, with $17.5 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Non-Current Deffered Revenue changed N/A year-over-year to $17.5 million; the TTM figure through Dec 2025 stood at $17.5 million (changed N/A YoY), while the FY2025 annual figure was $17.5 million, changed N/A from the prior year.
• Non-Current Deffered Revenue held at $17.5 million in Q4 2025 per DMIIU's latest filing, from $17.5 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $17.5 million in Q3 2025 and bottomed at $17.5 million in Q3 2025.